Infection prevention
in pathogen-specific reduction. AI-based hand-hygiene systems – especially those using computer vision or depth sensors – can observe many more opportunities than covert human observation and avoid some Hawthorne-effect limitations. A scoping review published in 2026 found that computer vision pathways dominated the literature and could achieve very high accuracy in setting-specific models, although generalisability was inconsistent.9
Economic
modelling further suggests that if electronic audit and feedback systems reduce HCAI incidence by around 15% or more, they could be cost-effective for the NHS, avoiding hundreds of infections and releasing substantial bed capacity. For SSI, CLABSI and CAUTI, the clearest AI
benefit to date is in surveillance and case identification. Semi-automated SSI surveillance models have reduced workload while maintaining good detection performance, and generative-AI-supported surveillance has shown the ability to classify CLABSI and CAUTI training scenarios accurately. These are meaningful gains for IPC teams because they free specialist time and may improve consistency, but they should not be confused with direct proof of reduced infection incidence.
Discussion The findings of this review suggest that healthcare is unusually well positioned to benefit from AI in infection control, but also that the field remains more mature technically than it is evidentially. England benefits from extensive mandatory surveillance, defined case categories, national dashboards and policy structures that explicitly support infection reduction and AMR control. These assets provide a strong substrate for model development, benchmarking and evaluation. By contrast, many health systems attempting AI in IPC first must build the surveillance architecture that the UK already possesses. However, this advantage does not eliminate
the translational gap. Most AI IPC studies remain at the level of model development or technical validation, with comparatively few routine clinical implementations and fewer still demonstrating robust outcome benefit. This is important because IPC is ultimately judged
in terms of prevented harm, not predictive elegance. A highly discriminative model that does not change behaviour, or that changes behaviour without reducing infection burden, may still be useful but should not be oversold. Clinical services should therefore prioritise use cases where AI is most likely to confer practical value in the short term. Three candidates stand out. First, risk-guided antimicrobial stewardship, especially around CDI and AMR, because process outcomes such as antibiotic-days of therapy are measurable and modifiable. Second, semi-automated surveillance, where workforce efficiencies, standardisation and timeliness are realistic gains even before pathogen reductions are seen. Third, Trust-level resistance and infection forecasting, where AI can support anticipatory resource planning and policy adaptation. These applications align well with existing UKHSA and NHS England data structures. A second key point is interpretability. In infection control, there is a premium on transparent logic because outputs may drive actions with direct patient impact, such as isolation or antimicrobial change. Models that cannot provide intelligible rationale are likely to face clinician resistance or generate unsafe over-reliance. The emerging emphasis on explainable AI, local feature importance and in-workflow presentation is therefore not
For hospital leaders and IPC teams, the implication is clear: AI should be implemented as part of carefully designed, evaluable intervention systems, not as a stand-alone technology acquisition.
22
www.clinicalservicesjournal.com I September 2026
merely a technical preference; it is a governance requirement for adoption in NHS settings. There are also several implementation
hazards. Alert fatigue is a major issue, especially when systems are added on top of already dense digital warning environments. Model drift is another concern: changing formularies, new diagnostics, ward reconfiguration or outbreak conditions can all degrade performance. Bias and inequity also require attention, particularly if models are trained in narrower case mixes and then applied across different Trust populations. Recent hand-hygiene and hospital-IPC reviews note that fairness assessment, workflow evaluation and pragmatic implementation science remain underdeveloped. Taken together, these observations support a cautious but proactive NHS strategy. AI should not be evaluated in isolation, and it should not be procured simply because it promises earlier detection. Rather, each deployment should be tied to a specific IPC bundle, a defined governance framework, and a prospectively agreed measurement plan using recognised HCAI metrics. The fact that many healthcare facilities already have strong surveillance comparators means that such a strategy is feasible and should be expected. In terms of limitations, this review is narrative
and not a systematic meta-analysis. It therefore does not provide pooled effect estimates or formal risk-of-bias scoring across all included studies. The contemporary literature is also heterogeneous with respect to endpoints, case definitions, settings and implementation maturity, limiting direct comparison. In addition, some UK implementation examples are currently described more fully in deployment reports and health-technology communications than in peer-reviewed outcome studies. These
pandpstock001 -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85